Equities analysts expect that NeoGenomics, Inc. (NASDAQ:NEO) will announce earnings per share (EPS) of $0.07 for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for NeoGenomics’ earnings, with estimates ranging from $0.05 to $0.09. NeoGenomics posted earnings of $0.06 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.7%. The firm is expected to report its next earnings report on Tuesday, February 18th.
According to Zacks, analysts expect that NeoGenomics will report full year earnings of $0.28 per share for the current fiscal year, with EPS estimates ranging from $0.26 to $0.30. For the next year, analysts anticipate that the firm will post earnings of $0.37 per share, with EPS estimates ranging from $0.33 to $0.42. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow NeoGenomics.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, October 29th. The medical research company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.01. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $99.38 million. During the same quarter in the previous year, the firm posted $0.05 earnings per share. The company’s quarterly revenue was up 51.5% compared to the same quarter last year.
NEO traded up $0.16 on Friday, reaching $23.06. The company had a trading volume of 7,109 shares, compared to its average volume of 669,673. NeoGenomics has a 1 year low of $11.05 and a 1 year high of $26.89. The stock has a market capitalization of $2.36 billion, a PE ratio of 178.31 and a beta of 0.94. The company has a quick ratio of 4.05, a current ratio of 4.24 and a debt-to-equity ratio of 0.24. The stock has a 50-day moving average price of $20.71 and a 200-day moving average price of $22.55.
In related news, insider George Cardoza sold 51,556 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $22.82, for a total transaction of $1,176,507.92. Following the completion of the transaction, the insider now directly owns 356,387 shares of the company’s stock, valued at $8,132,751.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven C. Jones sold 181,339 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $24.92, for a total transaction of $4,518,967.88. Following the transaction, the director now directly owns 245,234 shares of the company’s stock, valued at $6,111,231.28. The disclosure for this sale can be found here. Insiders sold 363,399 shares of company stock valued at $8,822,819 over the last ninety days. Corporate insiders own 8.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of NEO. Mason Street Advisors LLC lifted its position in NeoGenomics by 3.1% in the third quarter. Mason Street Advisors LLC now owns 35,266 shares of the medical research company’s stock valued at $674,000 after acquiring an additional 1,062 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its position in shares of NeoGenomics by 75.0% in the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 1,950 shares during the period. SG Americas Securities LLC raised its position in shares of NeoGenomics by 152.6% in the 3rd quarter. SG Americas Securities LLC now owns 42,084 shares of the medical research company’s stock valued at $805,000 after acquiring an additional 25,421 shares during the period. Moloney Securities Asset Management LLC acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at approximately $269,000. Finally, Synovus Financial Corp acquired a new stake in shares of NeoGenomics in the 3rd quarter valued at approximately $393,000. 84.48% of the stock is owned by hedge funds and other institutional investors.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: What is a Tariff?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.